SCHEMBL10000785

SCHEMBL10000785

CCc1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.69
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CD274 Q9NZQ7 1/20 0.50
HTR6 P50406 1/20 0.48
ALDH1A1 P00352 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 6/20 0.47
GAA P10253 2/20 0.47
THRB P10828 2/20 0.47
SLC9A1 P19634 2/20 0.47
ALOX5 P09917 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
S1PR4 O95977 1/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18551806 0.85 CD274 (0.67) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL282163 0.84 SOS1 (0.66) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL624093 0.82 ALDH1A1 (0.65) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL18014746 0.81 SOS1 (0.63) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL13719297 0.81 SOS1 (0.63) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL2056342 0.79 ALDH1A1 (0.62) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL5043758 0.79 ALDH1A1 (0.68) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL6400955 0.79 SOS1 (0.60) SOS1KMT2AMEN1L3MBTL1CD274
SCHEMBL805141 0.79 CYP2C19 (0.64) SOS1HTR6ALDH1A1SMN1; SMN2HTT
SCHEMBL13753966 0.79 MAOB (0.47) SOS1KMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2016-08-11 US disclosed
US-8163791-B2 Imidazole derivatives that induce apoptosis and their therapeutic uses INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2012-04-24 US disclosed
US-7888118-B2 induces differentiation of myoblasts or muscle fiber into neuron cells; drug screening; useful for treatment of neurodegenerative disorders, such as stroke, spinal cord injury, Parkinson's and Alzheimer's diseases; 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole (Neurodazine 1) INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2011-02-15 US disclosed
US-20100184097-A1 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION INDUSTRY-ACADEMIC CORPORATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-07-22 US disclosed
US-7718685-B2 4,5-bis(4-methoxyphenyl)imidizole compound inducing differentiation of myoblasts or muscle fibers and pharmaceutical compositions including said compound INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-05-18 US disclosed
US-20100105726-A1 IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2010-04-29 US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070123576-A1 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2007-05-31 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105726-A1 IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES NFATC1, AIFM1, TP53 SOS1 4385/4885KMT2A 4757/4885MEN1 4840/4885
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS BACE1, BACE2, PSEN2 SOS1 3326/4885KMT2A 3843/4885MEN1 3008/4885
US-20070123576-A1 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation TNNC1, TNNI3, PYGM SOS1 2354/4885KMT2A 2911/4885MEN1 3704/4885
US-20100184097-A1 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION MUSK, TNNI3, TNNC1 SOS1 1843/4885KMT2A 2316/4885MEN1 1955/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA SOS1 3915/4885KMT2A 700/4885MEN1 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.